The requested table can only be partially populated from the supplied records. Cd1d−/− has direct in vivo readout data; Cxcr3 data exists only from cancer cell lines and CAR T models (not Cxcr3−/− mice); Tgfb1−/− and Ccr5−/− have no data in the supplied sources and are marked as gaps rather than fabricated.
| Genotype | AST / Liver Enzymes | Histology | FACS | Luminex / Cytokines | Source |
|---|---|---|---|---|---|
| Cd1d−/− (C57BL/6, male, 10 wk) | Measured (AST/ALT, Reflovet Plus); steroid-induced hepatocellular injury still present in CD1d−/− mice → injury is CD1d-independent; glucosylceramide reduced liver enzymes | H&E, blinded pathologist; less marked steatosis in CD1d−/− vs WT on dexamethasone → steatosis is CD1d-dependent | Not reported | ELISA for IL-10 and IL-17 only (no Luminex panel); GC increased IL-10 and IL-17 | |
| Cxcr3 (knockout mice: NOT supplied) | Not reported | Not reported (IHC for CXCL10/CXCR3 in human breast tumors only) | FACS for CXCL10 (intracellular) and surface/intracellular CXCR3 in MDA-MB-435 cells; Ras downregulates CXCR3-B; CXCR3-A overexpression measured by flow cytometry in CAR T cells | Not Luminex; ELISA for CXCL9/10/11, IL-2, IFN-γ, TNF in CAR T co-cultures; CXCL10 secretion increased by Ras (<0.01) | |
| Tgfb1−/− | No supplied evidence — no study in the provided records measures AST, histology, FACS, or Luminex in Tgfb1-deficient models. | — | |||
| Ccr5−/− | No supplied evidence — no study in the provided records measures AST, histology, FACS, or Luminex in Ccr5-deficient models. | — | |||
Evidence gaps: The Cd1d−/− record lacks FACS and Luminex data (only two-cytokine ELISA) and did not compare WT and CD1d−/− littermates side-by-side in a single cohort, per author-reported limitations. CXCR3 findings come from in vitro cancer cell lines and immunodeficient NSG xenografts, so they cannot be mapped onto Cxcr3−/− mouse readouts. No Ccr5 or Tgfb1 data exists in the supplied evidence; any entries for these would be confabulation.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.